2020
Time to sputum culture conversion and its predictors among patients with multidrug-resistant tuberculosis in Hangzhou, China
Li Q, Lu M, Hsieh E, Wu L, Wu Y, Wang M, Wang L, Zhao G, Xie L, Qian HZ. Time to sputum culture conversion and its predictors among patients with multidrug-resistant tuberculosis in Hangzhou, China. Medicine 2020, 99: e23649. PMID: 33327347, PMCID: PMC7738096, DOI: 10.1097/md.0000000000023649.Peer-Reviewed Original ResearchConceptsInitial sputum culture conversionSputum culture conversionPoor treatment outcomesSuccessful treatment outcomeTreatment outcomesCulture conversionMDR-TBMultidrug-resistant tuberculosis patientsCox proportional hazards regressionMDR-TB treatmentMDR-TB patientsRetrospective cohort studyKaplan-Meier methodTreatment success rateInitiation of treatmentMultidrug-resistant tuberculosisProportional hazards regressionConsecutive negative culturesRisk of transmissionCohort studyTuberculosis patientsTreatment failureHazards regressionOutpatient treatmentInpatient treatmentThe Impact of Concurrent Antiretroviral Therapy and MDR-TB Treatment on Adverse Events.
Smith JP, Gandhi NR, Shah NS, Mlisana K, Moodley P, Johnson BA, Allana S, Campbell A, Nelson KN, Master I, Brust JCM. The Impact of Concurrent Antiretroviral Therapy and MDR-TB Treatment on Adverse Events. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2020, 83: 47-55. PMID: 31809360, PMCID: PMC6903405, DOI: 10.1097/qai.0000000000002190.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisConcurrent antiretroviral therapyMDR-TB patientsMDR-TB treatmentLaboratory adverse eventsAdverse eventsHIV coinfectionAntiretroviral therapyHIV statusConcurrent treatmentCommon clinical adverse eventsCommon laboratory adverse eventsCo-infected participantsColor discrimination testingMDR-TB therapyAntiretroviral therapy initiationFrequent adverse eventsClinical adverse eventsProspective observational studyFavorable treatment outcomesColor discrimination lossesTherapy initiationConcurrent therapyCreatinine clearanceVision loss
2014
Reducing Communication Delays and Improving Quality of Care with a Tuberculosis Laboratory Information System in Resource Poor Environments: A Cluster Randomized Controlled Trial
Blaya J, Shin S, Yagui M, Contreras C, Cegielski P, Yale G, Suarez C, Asencios L, Bayona J, Kim J, Fraser H. Reducing Communication Delays and Improving Quality of Care with a Tuberculosis Laboratory Information System in Resource Poor Environments: A Cluster Randomized Controlled Trial. PLOS ONE 2014, 9: e90110. PMID: 24721980, PMCID: PMC3982951, DOI: 10.1371/journal.pone.0090110.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntitubercular AgentsClinical Laboratory Information SystemsCommunicationDatabases, FactualDeveloping CountriesFemaleHumansLaboratoriesMaleMedical ErrorsMicrobial Sensitivity TestsMiddle AgedPeruPovertyProportional Hazards ModelsProspective StudiesQuality ImprovementQuality of Health CareResearch DesignTreatment OutcomeTuberculosisTuberculosis, Multidrug-ResistantYoung AdultConceptsIntervention health centersHealth centersDrug susceptibility testLaboratory information systemMDR-TB risk factorsMulti-drug resistant tuberculosisMDR-TB patientsPrimary health centersMain outcome measuresCulture convertCulture conversionResistant tuberculosisRisk factorsPatient outcomesClinical impactOutcome measuresDays less timePatientsPatient treatmentStudy designSusceptibility testsBaseline dataTrialsOnly studyTreatmentImproved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial
Padayatchi N, Abdool Karim SS, Naidoo K, Grobler A, Friedland G. Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial. The International Journal Of Tuberculosis And Lung Disease 2014, 18: 147-154. PMID: 24429305, PMCID: PMC4770013, DOI: 10.5588/ijtld.13.0627.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisMDR-TB patientsSequential treatment armAnti-tuberculosis treatmentAntiretroviral treatmentTreatment armsFirst-line anti-tuberculosis treatmentMultidrug-resistant tuberculosis patientsHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionOut-patient clinicDrug susceptibility resultsSAPiT trialTuberculosis patientsClinical outcomesEarly initiationTherapeutic effectVirus infectionMortality ratePatientsTherapeutic outcomesSmall sample sizeTreatmentSusceptibility resultsTuberculosis
2013
Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: retrospective-prospective cohort study from 2004 to 2007.
Anderson LF, Tamne S, Watson JP, Cohen T, Mitnick C, Brown T, Drobniewski F, Abubakar I. Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: retrospective-prospective cohort study from 2004 to 2007. Eurosurveillance 2013, 18 PMID: 24128699, DOI: 10.2807/1560-7917.es2013.18.40.20601.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntibiotics, AntitubercularAntitubercular AgentsChildChild, PreschoolDrug Resistance, Multiple, BacterialFemaleFluoroquinolonesHumansInfantInfant, NewbornMaleMicrobial Sensitivity TestsMiddle AgedMycobacterium tuberculosisPatient ComplianceProspective StudiesRetrospective StudiesSurveys and QuestionnairesTreatment OutcomeTuberculosis, Multidrug-ResistantUnited KingdomYoung AdultConceptsMultidrug-resistant tuberculosisTreatment outcomesRetrospective-prospective cohort studyWorld Health Organization targetMulti-drug resistant tuberculosisMDR-TB patientsMDR-TB treatmentMDR-TB casesFurther drug resistanceTreatment completion ratesSuccessful treatment outcomeUnited Kingdom guidelinesIndividualised regimensCohort studyMonths treatmentResistant tuberculosisTreatment completionInfectious casesDrug resistanceDrug sensitivitySuccessful outcomeOrganization targetBacteriostatic drugsOutcomesTreatmentA Pilot Study of an mHealth Application for Healthcare Workers: Poor Uptake Despite High Reported Acceptability at a Rural South African Community-Based MDR-TB Treatment Program
Chaiyachati KH, Loveday M, Lorenz S, Lesh N, Larkan LM, Cinti S, Friedland GH, Haberer JE. A Pilot Study of an mHealth Application for Healthcare Workers: Poor Uptake Despite High Reported Acceptability at a Rural South African Community-Based MDR-TB Treatment Program. PLOS ONE 2013, 8: e64662. PMID: 23724075, PMCID: PMC3665589, DOI: 10.1371/journal.pone.0064662.Peer-Reviewed Original ResearchConceptsAdverse event formsMDR-TB patientsMDR-TB therapyHealthcare workersMobile healthcare workersMDR-TB treatment programmeMultidrug-resistant tuberculosis epidemicPoor uptakeAdverse clinical eventsResource-poor settingsRural South African communityEvent formsMixed-methods evaluationClinical eventsSpecialty centersCommunity hospitalHCWs' perceptionsTuberculosis epidemicOwn careIntensive phaseHealth professionalsHealth interventionsPoor settingsTreatment programQualitative focus groupsAdverse Events in an Integrated Home-Based Treatment Program for MDR-TB and HIV in KwaZulu-Natal, South Africa
Brust JC, Shah NS, van der Merwe TL, Bamber S, Ning Y, Heo M, Moll AP, Loveday M, Lalloo UG, Friedland GH, Gandhi NR. Adverse Events in an Integrated Home-Based Treatment Program for MDR-TB and HIV in KwaZulu-Natal, South Africa. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2013, 62: 436-440. PMID: 23254152, PMCID: PMC3641171, DOI: 10.1097/qai.0b013e31828175ed.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisAdverse eventsAntiretroviral therapyCommon severe adverse eventsMDR-TB/HIVTreatment programConcurrent antiretroviral therapyMDR-TB patientsMDR-TB therapySevere adverse eventsHome-based treatment programHome-based care settingsRural KwaZulu-NatalMost patientsTherapy modificationConcurrent treatmentCare settingsHIVPatientsTherapyKwaZulu-NatalIntegrated HomeTolerabilityHypothyroidismTuberculosisRisk factors and timing of default from treatment for non-multidrug-resistant tuberculosis in Moldova
Jenkins HE, Ciobanu A, Plesca V, Crudu V, Galusca I, Soltan V, Cohen T. Risk factors and timing of default from treatment for non-multidrug-resistant tuberculosis in Moldova. The International Journal Of Tuberculosis And Lung Disease 2013, 17: 373-380. PMID: 23407226, PMCID: PMC3710709, DOI: 10.5588/ijtld.12.0464.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntitubercular AgentsContinuity of Patient CareFemaleHumansInstitutionalizationLeast-Squares AnalysisLinear ModelsMaleMedication AdherenceMoldovaMultivariate AnalysisPatient DischargePrisonersProportional Hazards ModelsRetrospective StudiesRisk FactorsSocioeconomic FactorsTime FactorsTreatment OutcomeTuberculosisConceptsMultidrug-resistant tuberculosisMDR-TB patientsRisk factorsHighest MDR-TB ratesDrug resistanceGreater lung pathologyMDR-TB ratesAnti-tuberculosis treatmentIndependent risk factorHuman immunodeficiency virusTB drug resistanceContinuity of careRoutine surveillance dataTuberculosis patientsResistant tuberculosisImmunodeficiency virusLung pathologyTreatment adherenceRetrospective analysisHigh riskPatientsSociodemographic factorsCommunity careSurveillance dataStudy period
2012
Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting
Gandhi N, Andrews J, Brust J, Montreuil R, Weissman D, Heo M, Moll A, Friedland G, Shah N. Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting. The International Journal Of Tuberculosis And Lung Disease 2012, 16: 90-97. PMID: 22236852, PMCID: PMC3302205, DOI: 10.5588/ijtld.11.0153.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAnti-Retroviral AgentsAntitubercular AgentsCD4 Lymphocyte CountCoinfectionDrug Resistance, Multiple, BacterialExtensively Drug-Resistant TuberculosisFemaleHIV InfectionsHumansMaleMarkov ChainsMonte Carlo MethodPrevalencePrognosisProportional Hazards ModelsRetrospective StudiesRisk AssessmentRisk FactorsSouth AfricaSurvival AnalysisTime FactorsTuberculosis, Multidrug-ResistantTuberculosis, PulmonaryConceptsHuman immunodeficiency virusXDR-TB patientsRisk factorsAntiretroviral therapyXDR-TBDrug-resistant (XDR) TBImmunosuppressed human immunodeficiency virusStrong independent risk factorHigh HIV prevalence settingsMDR-TB patientsTB treatment programsIndependent risk factorYear of diagnosisDrug-resistant tuberculosisHIV prevalence settingsCells/Principal risk factorsCase-control studyAmplification of resistanceHigh mortality rateART initiationHIV testingImmunodeficiency virusPrevalence settingsMortality rate
2011
Multiple Introductions of Multidrug-Resistant Tuberculosis into Households, Lima, Peru - Volume 17, Number 6—June 2011 - Emerging Infectious Diseases journal - CDC
Cohen T, Murray M, Abubakar I, Zhang Z, Sloutsky A, Arteaga F, Chalco K, Franke MF, Becerra MC. Multiple Introductions of Multidrug-Resistant Tuberculosis into Households, Lima, Peru - Volume 17, Number 6—June 2011 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2011, 17: 969-975. PMID: 21749756, PMCID: PMC3358204, DOI: 10.3201/eid1706.101471.Peer-Reviewed Original ResearchConceptsMDR-TB patientsMDR-TBMultidrug-resistant tuberculosisTB patientsOptimal treatment regimensMDR Mycobacterium tuberculosisDrug sensitivity testingHigh incidence areaRepetitive unit-variable number tandem repeatHousehold contactsTreatment regimensHousehold transmissionSecondary casesPatientsMycobacterium tuberculosisSensitivity testingCommunity exposureTuberculosisNumber tandem repeatTBSecond strainExposureRegimensSpoligotypingSpread of Extensively Drug-Resistant Tuberculosis in KwaZulu-Natal Province, South Africa
Moodley P, Shah NS, Tayob N, Connolly C, Zetola N, Gandhi N, Friedland G, Sturm AW. Spread of Extensively Drug-Resistant Tuberculosis in KwaZulu-Natal Province, South Africa. PLOS ONE 2011, 6: e17513. PMID: 21655324, PMCID: PMC3104985, DOI: 10.1371/journal.pone.0017513.Peer-Reviewed Original ResearchConceptsMDR-TB casesDrug-resistant tuberculosisXDR-TB casesXDR-TBDrug susceptibility test resultsExtensively Drug-Resistant TuberculosisMDR tuberculosis casesMDR-TB patientsXDR-TB patientsCulture-confirmed casesProvincial referral hospitalCross-sectional studyKwaZulu-Natal ProvinceSource of infectionTB casesNumber of hospitalsReferral hospitalSputum cultureTuberculosis casesScotland hospitalsPatientsHealthcare districtsHospitalClinical diagnosisLaboratory databaseCulture Conversion Among HIV Co-Infected Multidrug-Resistant Tuberculosis Patients in Tugela Ferry, South Africa
Brust JC, Lygizos M, Chaiyachati K, Scott M, van der Merwe TL, Moll AP, Li X, Loveday M, Bamber SA, Lalloo UG, Friedland GH, Shah NS, Gandhi NR. Culture Conversion Among HIV Co-Infected Multidrug-Resistant Tuberculosis Patients in Tugela Ferry, South Africa. PLOS ONE 2011, 6: e15841. PMID: 21253585, PMCID: PMC3017058, DOI: 10.1371/journal.pone.0015841.Peer-Reviewed Original ResearchConceptsMDR-TB patientsCulture conversion rateMDR-TB treatmentMonths of therapyAntiretroviral therapyHIV-coCulture conversionHIV co-infected patientsMultidrug-resistant tuberculosis patientsTiming of ARTMDR-TB therapyCo-infected patientsHIV-negative patientsSecond-line regimenSimilar cure ratesDays of initiationResource-limited settingsHIV prevalentART medicationsCD4 countMDR-TBTuberculosis patientsSputum cultureSuch patientsHIV status
2010
Predictors of Multidrug- and Extensively Drug-Resistant Tuberculosis in a High HIV Prevalence Community
Andrews JR, Shah NS, Weissman D, Moll AP, Friedland G, Gandhi NR. Predictors of Multidrug- and Extensively Drug-Resistant Tuberculosis in a High HIV Prevalence Community. PLOS ONE 2010, 5: e15735. PMID: 21209951, PMCID: PMC3012092, DOI: 10.1371/journal.pone.0015735.Peer-Reviewed Original ResearchConceptsDrug-resistant tuberculosisTB treatment failureXDR-TBHIV prevalence settingsRisk factorsTreatment failureOdds ratioMDR/XDR-TBOnly significant risk factorRetrospective case-control studyDrug resistanceMDR-TB patientsSignificant risk factorsStrong risk factorMultivariate logistic regressionTB drug resistanceCase-control studyHigh HIV prevalence communitiesDemographic risk factorsDrug susceptibility testing methodsHIV prevalence communitiesTB settingsClinical deteriorationMDR-TBTB treatment
2005
Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran
Mirsaeidi SM, Tabarsi P, Khoshnood K, Pooramiri MV, Rowhani-Rahbar A, Mansoori SD, Masjedi H, Zahirifard S, Mohammadi F, Farnia P, Masjedi MR, Velayati AA. Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran. International Journal Of Infectious Diseases 2005, 9: 317-322. PMID: 16183321, DOI: 10.1016/j.ijid.2004.09.012.Peer-Reviewed Original ResearchConceptsMultiple drug-resistant tuberculosisMore second-line drugsDrug-resistant tuberculosis treatmentMDR-TB patientsMDR-TB treatmentMasih Daneshvari HospitalDrug-resistant tuberculosisSecond-line drugsAppropriate treatment regimensProbable cureDrug regimenTreatment regimenComplete followTreatment regimensTuberculosis treatmentPatientsAverage durationRegimenTreatmentDrugsCureRegimensAmikacinHospitalFollow
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply